Author asks for validation of a small speculative long in ImmunityBio after a +35% move, citing ANKTIVA approval and regulatory updates.
IBRX — LONG Author holds a small speculative long position and is willing to hold for 1-2 years if a real runway develops. He notes IBRX now has a marketed product (ANKTIVA) in bladder cancer and additional regulatory/clinical updates, which he sees as potential durable inflection points rather than pure pipeline speculation. His main concern is that the recent +35% move may be sentiment-driven and ahead of fundamentals.
They have a marketed product (ANKTIVA) in bladder cancer, and there have been additional regulatory/clinical updates that are clearly driving interest.
This Reddit post, published January 16, 2026, features u/fourslider discussing IBRX. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/fourslider · Tickers: IBRX